Novartis AG EBITDA Margin 2010-2024 | NVS
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Novartis AG (NVS) over the last 10 years. The current EBITDA margin for Novartis AG as of September 30, 2024 is .
| Novartis AG EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2024-09-30 |
$49.94B |
$16.56B |
33.17% |
| 2024-06-30 |
$48.86B |
$14.70B |
30.08% |
| 2024-03-31 |
$47.73B |
$13.49B |
28.26% |
| 2023-12-31 |
$46.66B |
$13.31B |
28.53% |
| 2023-09-30 |
$41.66B |
$11.94B |
28.65% |
| 2023-06-30 |
$40.35B |
$13.77B |
34.11% |
| 2023-03-31 |
$41.69B |
$15.09B |
36.18% |
| 2022-12-31 |
$43.46B |
$14.91B |
34.31% |
| 2022-09-30 |
$50.20B |
$14.64B |
29.16% |
| 2022-06-30 |
$52.79B |
$14.28B |
27.05% |
| 2022-03-31 |
$53.00B |
$13.63B |
25.72% |
| 2021-12-31 |
$52.88B |
$11.69B |
22.11% |
| 2021-09-30 |
$56.14B |
$17.07B |
30.41% |
| 2021-06-30 |
$51.56B |
$14.09B |
27.34% |
| 2021-03-31 |
$49.88B |
$12.97B |
25.99% |
| 2020-12-31 |
$49.90B |
$13.30B |
26.64% |
| 2020-09-30 |
$45.83B |
$9.12B |
19.90% |
| 2020-06-30 |
$49.53B |
$12.60B |
25.44% |
| 2020-03-31 |
$49.93B |
$12.91B |
25.85% |
| 2019-12-31 |
$48.68B |
$12.41B |
25.49% |
| 2019-09-30 |
$47.86B |
$11.69B |
24.42% |
| 2019-06-30 |
$46.76B |
$10.20B |
21.81% |
| 2019-03-31 |
$46.39B |
$9.97B |
21.48% |
| 2018-12-31 |
$46.10B |
$10.09B |
21.90% |
| 2018-09-30 |
$47.37B |
$10.84B |
22.88% |
| 2018-06-30 |
$48.67B |
$10.95B |
22.50% |
| 2018-03-31 |
$49.51B |
$10.80B |
21.82% |
| 2017-12-31 |
$50.14B |
$10.35B |
20.65% |
| 2017-09-30 |
$49.58B |
$9.85B |
19.86% |
| 2017-06-30 |
$49.23B |
$11.27B |
22.89% |
| 2017-03-31 |
$49.41B |
$12.55B |
25.39% |
| 2016-12-31 |
$49.44B |
$14.44B |
29.22% |
| 2016-09-30 |
$49.63B |
$12.83B |
25.86% |
| 2016-06-30 |
$49.78B |
$12.65B |
25.40% |
| 2016-03-31 |
$50.00B |
$12.88B |
25.75% |
| 2015-12-31 |
$50.39B |
$13.12B |
26.04% |
| 2015-09-30 |
$50.94B |
$13.80B |
27.09% |
| 2015-06-30 |
$51.75B |
$14.11B |
27.27% |
| 2015-03-31 |
$52.81B |
$14.68B |
27.81% |
| 2014-12-31 |
$53.63B |
$14.55B |
27.13% |
| 2014-09-30 |
$52.60B |
$15.91B |
30.24% |
| 2014-06-30 |
$52.21B |
$15.65B |
29.98% |
| 2014-03-31 |
$51.54B |
$15.29B |
29.66% |
| 2013-12-31 |
$52.72B |
$15.45B |
29.30% |
| 2013-09-30 |
$49.87B |
$14.45B |
28.98% |
| 2013-06-30 |
$51.00B |
$14.98B |
29.37% |
| 2013-03-31 |
$52.26B |
$15.29B |
29.25% |
| 2012-12-31 |
$51.97B |
$15.08B |
29.01% |
| 2012-09-30 |
$57.49B |
$15.43B |
26.83% |
| 2012-06-30 |
$58.48B |
$15.62B |
26.71% |
| 2012-03-31 |
$59.07B |
$16.03B |
27.13% |
| 2011-12-31 |
$59.38B |
$16.76B |
28.23% |
| 2011-09-30 |
$58.84B |
$17.08B |
29.02% |
| 2011-06-30 |
$56.63B |
$16.52B |
29.18% |
| 2011-03-31 |
$53.43B |
$15.44B |
28.91% |
| 2010-12-31 |
$51.56B |
$15.10B |
29.29% |
| 2010-09-30 |
$50.24B |
$14.36B |
28.58% |
| 2010-06-30 |
$48.71B |
$13.78B |
28.29% |
| 2010-03-31 |
$47.53B |
$13.07B |
27.50% |
| 2009-12-31 |
$45.10B |
$11.69B |
25.93% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$223.511B |
$45.440B |
|
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
|
